
News|Articles|July 30, 2025
Could targeting retinal non-perfusion be the key to achieving true disease modification in diabetic retinopathy?
Advertisement
Sponsored Supplement:
The triad of inflammation, neuropathy, and vasculopathy plays a key role in the development and progression of diabetic retinopathy (DR).1 Dr. Varun Chaudhary and Dr. Patrick Bussfeld, discuss how retinal non-perfusion (RNP) specifically drives disease progression and why it should be explored as a treatment target.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Regeneron receives another CRL for its Eylea 8 mg
2
Eli Lilly to acquire Adverum Biotechnologies
3
Anti-VEGF innovations in retinal disease: From molecules to medicine
4
Topcon Healthcare seeks to advance company through acquisition and new investment
5

















































.png)


